JP2015511221A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511221A5
JP2015511221A5 JP2014553763A JP2014553763A JP2015511221A5 JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5 JP 2014553763 A JP2014553763 A JP 2014553763A JP 2014553763 A JP2014553763 A JP 2014553763A JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5
Authority
JP
Japan
Prior art keywords
seq
fxii
pharmaceutical composition
composition according
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553763A
Other languages
English (en)
Japanese (ja)
Other versions
JP6243854B2 (ja
JP2015511221A (ja
Filing date
Publication date
Priority claimed from EP12153341.8A external-priority patent/EP2623110A1/en
Application filed filed Critical
Publication of JP2015511221A publication Critical patent/JP2015511221A/ja
Publication of JP2015511221A5 publication Critical patent/JP2015511221A5/ja
Application granted granted Critical
Publication of JP6243854B2 publication Critical patent/JP6243854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553763A 2012-01-31 2013-01-31 神経炎症性障害の処置のための第xii因子阻害剤 Active JP6243854B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261592652P 2012-01-31 2012-01-31
US61/592,652 2012-01-31
EP12153341.8A EP2623110A1 (en) 2012-01-31 2012-01-31 Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP12153341.8 2012-01-31
PCT/EP2013/051832 WO2013113774A1 (en) 2012-01-31 2013-01-31 Factor xii inhibitors for the treatment of neurological inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2015511221A JP2015511221A (ja) 2015-04-16
JP2015511221A5 true JP2015511221A5 (enExample) 2016-01-14
JP6243854B2 JP6243854B2 (ja) 2017-12-06

Family

ID=45554534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553763A Active JP6243854B2 (ja) 2012-01-31 2013-01-31 神経炎症性障害の処置のための第xii因子阻害剤

Country Status (11)

Country Link
US (1) US9957329B2 (enExample)
EP (2) EP2623110A1 (enExample)
JP (1) JP6243854B2 (enExample)
KR (1) KR102067394B1 (enExample)
CN (1) CN104080470B (enExample)
AU (1) AU2013200498B2 (enExample)
CA (1) CA2862903C (enExample)
DK (1) DK2809336T3 (enExample)
ES (1) ES2687018T3 (enExample)
PL (1) PL2809336T3 (enExample)
WO (1) WO2013113774A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのfxii阻害剤
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
EP3068424B1 (en) 2013-11-13 2020-09-09 Shire ViroPharma LLC Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR101744959B1 (ko) 2014-12-05 2017-06-12 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
EP3240570B1 (en) 2015-01-02 2025-09-24 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor xii
JPWO2016114386A1 (ja) * 2015-01-15 2017-10-19 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患治療剤
EA201890340A1 (ru) 2015-07-21 2018-09-28 Дайэкс Корп. Моноклональное антитело-ингибитор фактора xiia
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
CA3062123A1 (en) * 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
BR112020011240A2 (pt) * 2017-12-15 2020-11-24 Csl Limited uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica
EA202190056A1 (ru) 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
WO2021253662A1 (zh) * 2020-06-16 2021-12-23 宁波康善生物科技有限公司 抗fxii纳米抗体或其抗原结合片段及其应用
WO2025019789A1 (en) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
CN120192392B (zh) * 2025-05-23 2025-09-05 昆明医科大学 一种版纳绳蚋抗栓肽Sibakazin及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
GB9800817D0 (en) * 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
BR0317404A (pt) 2002-12-20 2005-11-16 Axis Shield Diagnostics Ltd Variantes do fator xiia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス, インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005318464B2 (en) * 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
EP3028716B1 (en) * 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
JP2010518039A (ja) * 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
CN102369021B (zh) 2008-12-19 2016-09-07 宏观基因有限公司 共价双抗体及其用途
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
RS66465B1 (sr) * 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe

Similar Documents

Publication Publication Date Title
JP2015511221A5 (enExample)
JP6656926B2 (ja) pKal関連疾病の評価、アッセイおよび治療
CA2901225C (en) Treatment and prevention of remote ischemia-reperfusion injury
TWI585103B (zh) 抗baff抗il-17雙特異性抗體
AU2014301041B2 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
JP2022023049A (ja) バイオ医薬組成物
JP2013517783A5 (enExample)
JP2016511823A (ja) ブラジキニン媒介障害の評価および治療
US7354585B2 (en) Methods of treating coagulapathic or thrombotic disorders
JP2019506839A5 (enExample)
JP2019038834A (ja) 分泌様免疫グロブリンを含む組成物
JP2013542914A5 (enExample)
CA2795168A1 (en) Factor xii inhibitors for treating interstitial lung disease
KR20160089368A (ko) 자가면역 질환의 진단 및 치료
WO2018039514A1 (en) Antibody-mediated neutralization of ebolaviruses
JP2017524675A5 (enExample)
CN106029884B (zh) 新型抗人pai-1抗体
JP2013539354A5 (enExample)
KR20230030644A (ko) 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
CA3184718A1 (en) Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
JP2019055949A5 (enExample)
JP7685957B2 (ja) プロテアーゼネキシン-1に対する立体構造的な単一ドメイン抗体及びその使用
US12497462B2 (en) Anti-CD26 proteins and uses thereof
US20230174666A1 (en) Anti-cd26 proteins and uses thereof